Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593539 | 0.81 | TNF (0.30) | TNF | |
| SCHEMBL457469 | 0.81 | ABL1 (0.30) | — | |
| SCHEMBL3009486 | 0.79 | — | — | |
| SCHEMBL13421281 | 0.79 | ABL1 (0.35) | TNF | |
| SCHEMBL10279496 | 0.79 | — | — | |
| SCHEMBL3025259 | 0.79 | PDE10A (0.34) | — | |
| SCHEMBL23547410 | 0.78 | HAVCR2 (0.31) | — | |
| SCHEMBL31285448 | 0.75 | TYK2 (0.34) | — | |
| SCHEMBL3719864 | 0.73 | MALT1 (0.31) | — | |
| SCHEMBL2359200 | 0.73 | NAPRT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | claimed |
| EP-3189055-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-12 | — | — | EP | claimed |
| WO-2016034507-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-10 | — | — | WO | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-119591600-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119591599-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024254536-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-114423756-B | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011013729-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TNF 4825/4885 |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | TNF 4776/4885 |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | TTBK1, TTK, TTBK2 | TNF 4780/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | TNF 2938/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | TNF 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.